Compare GSK plc (GSK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while Direxion Daily TSLA Bull 2X Shares trades at $10.48 (market cap $3.97B). The key difference: GSK plc is far larger — about 23.1× Direxion Daily TSLA Bull 2X Shares's market cap, and GSK plc pays a 3.9% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| GSK | TSLL | |
|---|---|---|
Market Cap | $91.88B | $3.97B |
Volume | 7,730,529 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $23.03 |
52-Week Low | $43.24 | $6.74 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.43, up 2.76% with neutral technical signals. The leveraged ETF tracks Tesla's daily performance, showing recent strength tied to Tesla's Cybercab event anticipation. Moving averages indicate bullish momentum while oscillators remain neutral, with RSI suggesting potential overbought conditions at shorter timeframes.
As a leveraged ETF, TSLL carries amplified risk from Tesla's volatility and daily reset mechanics. Recent news highlights both opportunity from Tesla catalysts and structural risks where investors can lose money even when Tesla rises. The ETF's performance depends entirely on Tesla's stock movement and market sentiment toward electric vehicle innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
